


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1 (Currently amended). A pharmaceutical composition for inhaled use in the respiratory tract of a mammal, comprising a compound according to Formula (I) hereinbelow:



wherein

~~R1 is selected from the group consisting of straight or branched chain lower alkyl group having from 1 to 6 carbon atoms;~~

R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl ~~groups~~ (having from 1 to 6 carbon atoms), cycloalkyl ~~groups~~ (having from 5 to 6 carbon atoms), ~~cycloalkyl alkyl (having 6 to 10 carbon atoms)~~, 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms, and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms; and

X⁻ represents an anion associated with the positive charge of the N atom; and a pharmaceutically acceptable carrier or diluent suitable for oral or nasal inhalation.

2 (currently amended). A pharmaceutical composition compound according to claim 1 wherein the orientation of the alkyl chain attached to the tropane ring is endo.

3 (currently amended). A pharmaceutical composition compound according to claim 2 wherein the compound of Formula (I) is selected from the group consisting of:

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;
and

(3-*endo*)-3-(2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane 4-methylbenzenesulfonate ÷ ..

4 (currently amended). A pharmaceutical composition compound according to claim 1 wherein X⁻ is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

5. (Cancelled)

6. (currently amended) A method of inhibiting the binding of acetylcholine to a acetylcholine receptor in a mammal in need thereof, which comprises contacting the acetylcholine receptor with an effective amount of a compound composition according to claim 1, and wherein the method of contacting the receptor with the composition is via inhalation by the mouth or nose of the mammal.

7. (currently amended) A method of treating a disease by inhibiting the binding of acetylcholine to a M₃ muscarinic acetylcholine receptor mediated disease, in the respiratory tract of a mammal in need thereof, which comprises contacting the M₃ muscarinic acetylcholine receptor with an effective amount of a compound composition according to claim 1 and wherein the method of contacting the receptor with the composition is via inhalation by the mouth or nose of the mammal.

8. (currently amended) A method according to claim 7 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and/or allergic rhinitis.

9. (currently amended) A method according to claim 7 wherein administration is via inhalation via the mouth or nose.

10. (original) A method according to claim 7 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.

11.(currently amended) A method according to claim 7 wherein the composition compound is administered to a human and has a duration of action of 12 hours or more for a dose of up to 1 mg and the mammal is a human.

12. (currently amended) A method according to claim 11 wherein the composition compound has a duration of action of 24 hours or more.

13. (currently amended) A method according to claim 12 wherein the composition compound has a duration of action of 36 hours or more.

14. (new) A method according to claim 7 wherein administration is via inhalation via the nose.

15. (new) A method of treating chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema or allergic rhinitis in a human in need thereof, comprising administering to said human by inhalation via the mouth or nose, an effective amount of a composition according to Claim 1.